A cross-sectional cohort study with microvascular complications in patients with type 2 diabetes with and without hypothyroidism

被引:5
|
作者
Johnson, Louise [1 ]
Rayner, Brian [2 ,3 ]
机构
[1] Montana Hosp, Pretoria, South Africa
[2] Univ Cape Town, Div Nephrol & Hypertens, Cape Town, South Africa
[3] Univ Cape Town, Kidney & Hypertens Res Unit, Cape Town, South Africa
关键词
hypothyroidism; type; 2; diabetes; microvascular and macrovascular complications; SUBCLINICAL HYPOTHYROIDISM; ASSOCIATION; RISK;
D O I
10.5830/CVJA-2019-036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Previous reports have suggested an as between hypothyroidism and macrovascular complications in type 2 diabetes (T2DM) but the association with microvascular complications is not well documented. This study aimed to determine whether there were significant differences in these complications in patients with T2DM with and without hypothyroidism. Methods: This was a retrospective, cross-sectional, case-control study from a single centre specialising in diabetes in South Africa. T2DM was defined by American Diabetes Association criteria. The cases were all patients treated for hypothyroidism and the controls were clinically and biochemically confirmed euthyroid. who were under follow up between 1 January and 1 July 2016. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) of < 60 ml/min. determined by the CKD-epidemiology collaboration equation (CKD-EPI) and/or albumin/creatinine ratio > 3 mg/mmol. Diabetic retiuopathy (DR) was defined as the presence of aneurysms, bleeds, exudates and new vessel formation on the retina examined by an ophthalmologist. Diabetic peripheral neuropathy (DPN) was defined as the presence of symptoms. loss of 128-Hz sensation and abnormal 10-gm monofilament. Cardiovascular disease (CVD) was defined as the presence of major adverse cardiovascular events (MACE). Results: there were 148 cases and 162 controls. Compared to the controls, the cases were older (65.6 vs 59.4 years, p < 0.00001), more likely to be female (67.0 vs 30.5%, p < 0.00011 and white (89.2 vs 79.6%, p = 0.02, have a lower HbA(lo) level (7.5 vs 8.2%. p = 0.0001), eGFR (64.4 vs 72.7 ml/min, p = 0.0006) and triglyceride level (2.18 vs 2.55 mmol/l, p = 0.04). have a higher high-density lipoprotein cholesterol level (1.13 vs 1.02 mmol/l. p = 0.001), a longer duration of diabetes (14.8 vs 11.6 years, p = 0.001) and using fewer antidiabetic agents (1.82 vs 2.19. p = 0.001). There was a higher prevalence of CKD (44 vs 57.8%, p = 0.03) and CVD (59.3 vs 45.3, p = 0.06), and a trend towards higher DR (66.7 vs 47.6, p = 0.09). There was no difference in body mass index, hypertension. low-density lipoprotein cholesterol level (all patients received stain therapy). DPN and amputations. After adjusting for confounding 1-actors, then; was no association between CKD and DR, and hypothyroidism, but the trend to association with CVD persisted (OR 1.97. p = 0.07). Conclusions: Hypothyroidism in T2DM was not associated with microvascular disease after adjusting for confounding factors. There was a nearly two-fold risk of CVD. The study is limited by the retrospective and observational design.
引用
收藏
页码:5 / 8
页数:4
相关论文
共 50 条
  • [31] Association of subclinical hypothyroidism with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A cross-sectional study
    Sheikhi, Vahid
    Heidari, Zahra
    ADVANCED BIOMEDICAL RESEARCH, 2022, 11 (01):
  • [32] Time in range and complications of diabetes: a cross-sectional analysis of patients with Type 1 diabetes
    Bezerra, Marta Fernandes
    Neves, Celestino
    Neves, Joao Sergio
    Carvalho, Davide
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [33] Time in range and complications of diabetes: a cross-sectional analysis of patients with Type 1 diabetes
    Marta Fernandes Bezerra
    Celestino Neves
    João Sérgio Neves
    Davide Carvalho
    Diabetology & Metabolic Syndrome, 15
  • [34] Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study
    Cea-Calvo, Luis
    Conthe, Pedro
    Gomez-Fernandez, Pablo
    de Alvaro, Fernando
    Fernandez-Perez, Cristina
    CARDIOVASCULAR DIABETOLOGY, 2006, 5 (1)
  • [35] Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study
    Luis Cea-Calvo
    Pedro Conthe
    Pablo Gómez-Fernández
    Fernando de Alvaro
    Cristina Fernández-Pérez
    Cardiovascular Diabetology, 5
  • [36] Early changes of arterial elasticity in Type 1 diabetes with microvascular complications - A cross-sectional study from childhood to adulthood
    Benitez-Aguirre, P. Z.
    Januszewski, A. S.
    Cho, Y. H.
    Craig, M. E.
    Jenkins, A. J.
    Donaghue, K. C.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (12) : 1674 - 1680
  • [37] Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study
    Soedamah-Muthu, SS
    Chaturvedi, N
    Teerlink, T
    Idzior-Walus, B
    Fuller, JH
    Stehouwer, CDA
    JOURNAL OF INTERNAL MEDICINE, 2005, 258 (05) : 450 - 459
  • [38] Systolic dysfunction in asymptomatic type 2 diabetic patients, a harbinger of microvascular complications: A cross-sectional study from North India
    Roy, Shankar
    Kant, Ravi
    Kumar, Barun
    Khapre, Meenakshi
    Bairwa, Mukesh
    DIABETES & VASCULAR DISEASE RESEARCH, 2020, 17 (04):
  • [39] Quality of life in patients with type 2 diabetes mellitus: a cross-sectional study
    Sionti, Vasiliki
    Papageorgiou, Giorgos
    Peschos, Dimitrios
    Charalambous, George
    Kotrotsiou, Evangelia
    Christodoulides, Pavlos
    Zakopoulou, Victoria
    Gouva, Mary
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2019, 13 (01) : 57 - 67
  • [40] Predictors of Medication Adherence in Patients with Type 2 Diabetes: A Cross-Sectional Study
    Zeidi, Isa Mohammadi
    Maleki, Aisa
    Najafpour, Zahra
    Moosavi, Saeideh
    Kalhor, Rohollah
    CLINICAL DIABETOLOGY, 2023, 12 (04): : 253 - 260